8-K: Altimmune Appoints Gregory Weaver as New Chief Financial Officer

Altimmune, Inc. has appointed Gregory Weaver as its new Chief Financial Officer, effective November 11, 2024.

Summary

• Altimmune has appointed Gregory Weaver as Chief Financial Officer, effective November 11, 2024.
• Mr. Weaver will be responsible for the company's finance and accounting functions, including SEC reporting and investor relations.
• He has over 25 years of experience in finance within the life sciences industry, including roles at Cognito Therapeutics, atai Life Sciences, and other biotech companies.
• Mr. Weaver's compensation includes an annual salary of $475,000, a target bonus of 40% of his base salary, and equity grants of 225,000 stock options and 75,000 restricted stock units.
• The stock options and restricted stock units vest over a period of four years, subject to continued employment.
• Mr. Weaver is also eligible for severance benefits if terminated without cause or resigns for good reason, including up to 12 months of salary and COBRA coverage.
• Andrew Shutterly, the previous Interim CFO, has transitioned to the role of Corporate Controller.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of an experienced CFO and the company's forward-looking statements. The risks mentioned are standard for a clinical-stage biotech company.

Positives

• The appointment of Gregory Weaver brings a seasoned financial executive with over 25 years of experience in the life sciences industry.
• Mr. Weaver has a strong track record, including leading a $225 million IPO at atai Life Sciences.
• His experience includes capital market transactions, manufacturing and R&D investments, product launches, and M&A transactions.
• The compensation package includes a competitive base salary, bonus potential, and equity grants, aligning his interests with the company's success.
• The transition of Andrew Shutterly to Corporate Controller ensures continuity in the finance department.

Risks

• The document mentions forward-looking statements are subject to numerous assumptions, risks, and uncertainties.
• These risks include delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy.
• There are also risks related to the reliability of study results, adverse effects from product candidates, and the success of future clinical trials.

Future Outlook

The company anticipates that Mr. Weaver's experience will be valuable as they advance their lead program, pemvidutide, and continue to build value. The company also notes that there are multiple significant milestones on the horizon.

Management Comments

• Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune, stated that they are pleased to welcome Greg to Altimmune's executive team during a pivotal time in their evolution.
• Mr. Weaver stated that pemvidutide is a unique and highly promising product candidate and he is excited to play a role in Altimmune's future success.

Industry Context

The appointment of a seasoned CFO like Gregory Weaver is a common move for clinical-stage biopharmaceutical companies as they progress through clinical trials and approach potential commercialization. His experience in capital markets and M&A is particularly relevant for a company like Altimmune, which may need to raise additional capital or consider strategic partnerships.

Comparison to Industry Standards

• The compensation package for Mr. Weaver, including a $475,000 base salary, 40% target bonus, and equity grants, is generally in line with industry standards for CFOs at publicly traded biotech companies of similar size and stage.
• For example, CFOs at comparable companies such as Atossa Therapeutics (where Mr. Weaver previously served as interim CFO) and other clinical-stage biotechs typically receive similar base salaries and equity incentives.
• The vesting schedule for the equity grants, with 25% vesting after one year and the remainder over the following three years, is also a common practice to ensure long-term alignment with the company's goals.
• Severance packages including 12 months of salary and COBRA coverage are also standard for executive-level positions in the biotech industry.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO positively, potentially increasing investor confidence.
• Employees will have a new leader in the finance department, which may impact team dynamics and processes.
• The appointment of a permanent CFO may provide more stability and direction for the company's financial strategy.

Next Steps

• Mr. Weaver will assume his responsibilities as CFO, leading the company's finance and accounting functions.
• The company will continue to advance the development of pemvidutide and other product candidates.
• The company will continue to monitor and manage the risks associated with clinical trials and regulatory approvals.

Key Dates

Keywords

Chief Financial Officer, CFO, Gregory Weaver, Altimmune, executive appointment, biopharmaceutical, finance, equity grants, severance, compensation, pemvidutide